Minnesota is currently home to 2058 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact
Recruiting
Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) has been shown in clinical trials, registries, and meta-analyses to reduce recurrent events after PCI. This is accomplished by improving the angiographic result with lesion and vessel assessment to guide stent selection and implantation and intravascular imaging following stent implantation to ensure an adequate treatment endpoint has been achieved. Despite extensive literature supporting the use of IVUS in PCI, util... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: St. Luke's Hospital of Duluth, Duluth, Minnesota
Conditions: Atherosclerosis
Pulmonary Hypertension Association Registry
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
05/14/2024
Locations: University of Minnesota Health, Minneapolis, Minnesota
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
Recruiting
This clinical trial evaluates the use of a tool kit, Stress, Affect, Language and Speech Analysis (SALSA), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Study of DF9001 in Patients With Advanced Solid Tumors
Recruiting
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Solid Tumor, Adult
A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis
Recruiting
The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle gel. It is a randomized, double-blind, vehicle-controlled trial. Approximately 60 subjects will be enrolled. Subjects will apply their assigned investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12-weeks post final application for a total of approximately 16-weeks of required participation in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Minnesota Clinical Study Center, New Brighton, Minnesota
Conditions: Seborrheic Keratosis
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Recruiting
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Recruiting
Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This first study will enroll participants with melanoma, as melanoma cancer has been shown to be able to attract MDSCs. The study will begin to determine if SX-682 is a safe and effective treatment of melanoma. It is thought that SX-682 will b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Melanoma Stage Iii, Melanoma Stage Iv
Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
Recruiting
This project includes two projects. One is looking for new genes that cause Charcot Marie Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify the symptoms a person has.
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2024
Locations: University of Minnesota, Maple Grove, Minnesota
Conditions: Charcot-Marie-Tooth Disease, Type Ia (Disorder), HMSN
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
Recruiting
This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Charcot Marie Tooth Disease
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
Recruiting
This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic cath... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Duodenal Neoplasm, Pancreatic Neoplasm
Neurostimulation for Treatment of Chronic Upper Limb Pain After Brachial Plexus Injury
Recruiting
The purpose of this study is to see how much pain intensity is affected by high frequency spinal cord stimulation therapy in individuals with serious brachial plexus injury.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Brachial Plexus Injury
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
Recruiting
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Myelofibrosis, Indolent Systemic Mastocytosis